Similar articles

• A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis.

  Cudkowicz ME, Shefner JM, Schoenfeld DA, Brown RH Jr, Johnson H, Qureshi M, Jacobs M, Rothstein JD, Appel SH, Pascuzzi RM, Heiman-Patterson TD, Donofrio PD, David WS, Russell JA, Tandan R, Pioro EP, Felice KJ, Rosenfeld J, Mandler RN, Sachs GM, Bradley WG, Raynor EM, Baquis GD, Belsh JM, Novella S, Goldstein J, Hulihan J; Northeast ALS Consortium. Cudkowicz ME, et al. Neurology. 2003 Aug 26;61(4):456-64. doi: 10.1212/wnl.61.4.456. Neurology. 2003. PMID: 12939417 Clinical Trial.
• Gender-based effect of statins on functional decline in amyotrophic lateral sclerosis.

  Nefussy B, Hirsch J, Cudkowicz ME, Drory VE. Nefussy B, et al. J Neurol Sci. 2011 Jan 15;300(1-2):23-7. doi: 10.1016/j.jns.2010.10.011. Epub 2010 Nov 5. J Neurol Sci. 2011. PMID: 21056430
• Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).

  Miller RG, Mitchell JD, Lyon M, Moore DH. Miller RG, et al. Amyotroph Lateral Scler Other Motor Neuron Disord. 2003 Sep;4(3):191-206. Amyotroph Lateral Scler Other Motor Neuron Disord. 2003. PMID: 13129806 Review.
• Functional outcome measures as clinical trial endpoints in ALS.

  Traynor BJ, Zhang H, Shefner JM, Schoenfeld D, Cudkowicz ME; NEALS Consortium. Traynor BJ, et al. Neurology. 2004 Nov 23;63(10):1933-5. doi: 10.1212/01.wnl.0000144345.49510.4e. Neurology. 2004. PMID: 15557515 Clinical Trial.
• The tolerability of riluzole in the treatment of patients with amyotrophic lateral sclerosis.

  Bensimon G, Doble A. Bensimon G, et al. Expert Opin Drug Saf. 2004 Nov;3(6):525-34. doi: 10.1517/14740338.3.6.525. Expert Opin Drug Saf. 2004. PMID: 15500412 Review.